Top Line: Data continues to accumulate that hypofractionated regional nodal irradiation is as effective and safe as conventional fractionation.
The Study: Relatively recent trials such as HypoG-01 and Skagen Trial 1 have shown similar treatment outcomes and no excess adverse effects from hypofractionated RNI. These trials specifically covered regional nodes, but it’s unclear how specifically they mandated IMN coverage. HypoMast-IMNI is another recent trial to add to the mix that was specifically designed to test the safety of hypofractionation when covering the IMNs. The trial included 1494 patients with high risk breast cancer (pT1-4N2-3, pT3-4N1, or pT1-2N1 disease with additional high-risk factors) who were planned to have RNI with IMN coverage after mastectomy. Reconstruction was allowed, but only a small proportion had it. They were randomized to receive 50 Gy in 25 fractions or 42.56 Gy in 16 fractions. At 5 years, the cumulative incidence of locoregional recurrence was noninferior with hypofractionation (1.7% v 2.2%). There were no differences in rates of DFS (88.5% v 89.4%) or OS (95.1% v 96.1%). Notably, the rate of grade 2+ skin effects was significantly lower with hypofractionation (1.7% v 12.2%). Hypofractionation did not increase the rate of arm lymphedema.
TBL: Moderate hypofractionation is as safe and effective as conventional fractionation with possibly less acute skin effects in patients receiving postmastectomy RNI with inclusion of the IMN for breast cancer. | Wang, J Clin Oncol 2026
The Study: Relatively recent trials such as HypoG-01 and Skagen Trial 1 have shown similar treatment outcomes and no excess adverse effects from hypofractionated RNI. These trials specifically covered regional nodes, but it’s unclear how specifically they mandated IMN coverage. HypoMast-IMNI is another recent trial to add to the mix that was specifically designed to test the safety of hypofractionation when covering the IMNs. The trial included 1494 patients with high risk breast cancer (pT1-4N2-3, pT3-4N1, or pT1-2N1 disease with additional high-risk factors) who were planned to have RNI with IMN coverage after mastectomy. Reconstruction was allowed, but only a small proportion had it. They were randomized to receive 50 Gy in 25 fractions or 42.56 Gy in 16 fractions. At 5 years, the cumulative incidence of locoregional recurrence was noninferior with hypofractionation (1.7% v 2.2%). There were no differences in rates of DFS (88.5% v 89.4%) or OS (95.1% v 96.1%). Notably, the rate of grade 2+ skin effects was significantly lower with hypofractionation (1.7% v 12.2%). Hypofractionation did not increase the rate of arm lymphedema.
TBL: Moderate hypofractionation is as safe and effective as conventional fractionation with possibly less acute skin effects in patients receiving postmastectomy RNI with inclusion of the IMN for breast cancer. | Wang, J Clin Oncol 2026

